B cells are exposed to high levels of CD40 ligand (CD40L, CD154) in chronic inflammatory diseases. In addition, B cells expressing both CD40 and CD40L have been identified in human diseases such as autoimmune diseases and lymphoma. However, how such constitutively CD40-activated B cells under inflammation may impact on T cell response remains unknown. Using a mouse model in which B cells express a CD40L transgene (CD40LTg) and receive autocrine CD40/CD40L signaling, we show that CD40LTg B cells stimulated memory-like CD4 and CD8 T cells to express IL-10. This IL-10 expression by CD8 T cells was dependent on IFN-I and programmed cell death protein 1, and was critical for CD8 T cells to counterregulate their overactivation. (2) . CD40L derived from platelets has been shown to modulate adaptive immune response (3) . In multiple sclerosis patients, B cells had a trait of CD40-activated B cells and stimulated CD8 T cells in vitro via IL-15 (4) . Moreover, CD40L is functionally expressed on some B cells in patients with EBV infection (5) , autoimmune diseases (6) (7) (8) , and lymphoma (9) (10) (11) . In B cell lymphoma, this autonomous CD40/CD40L interaction has been shown to increase their survival through constitutive NF-kB and NFAT activation (12, 13) . These findings support the hypothesis that the heightened B cell CD40/CD40L signaling due to elevated CD40L expression during chronic inflammatory diseases changes B cell functions and has an impact on ongoing immune response through altered B cell reactivity.
C D40-CD154 (CD40 ligand [CD40L], CD40L) interaction delivers a critical costimulatory signal for B cell differentiation and function (1). CD40L is highly expressed by activated T cells as well as by platelets and various other cell types under chronic inflammatory diseases such as autoimmune diseases
In this study, we employed CD40L transgenic (CD40LTg) mice that express CD40L under the IgVH promoter specifically on B cells (14) . Thus, CD40LTg mice serve as a model for human diseases in which B cells abnormally express CD40L and are exposed to excessive CD40/CD40L signaling under chronic inflammation. Based on their phenotype, B cells in CD40LBTg mice are not constitutively activated (14, 15) . However, binding of CD40L or anti-CD40 Ab breaks up the CD40 and CD40L complex formed on the cell surface of B cells and triggers cis activation of B cells (16) , as evidenced by robust NF-kB-1 activation (15), without triggering trans-activation of dendritic cells (DCs) (16) . This augmented B cell-specific CD40/CD40L signaling enhanced the magnitude of primary Ag-specific humoral response as a result of premature termination of ongoing germinal center response (15, 16) . Moreover, aged CD40LBTg mice have been shown to develop B cell-mediated lupus-like disease and colitis with autoantibody production (14, 17) .
In this study, we show that CD40LTg B cells stimulated memory-like CD4 and CD8 T cells to express IL-10. Furthermore, in a RAG-1 2/2 colitis model, adoptive cotransfer of CD40LTg B cells could suppress inflammatory CD8 T cell response by inducing IL-10 expression and regulated CD8 T cell-mediated colitis.
Materials and Methods
Mice, immunization, and inflammatory challenge
, C57BL/6-Tg(TcraTcrb)1100Mjb/J (OT-I), and C57BL/6-Tg (TcraTcrb)425Cbn/J (OT-II) mice were all on a C57BL6/J background and were purchased from The Jackson Laboratory, as were C57BL6/J mice. All other mice used were on a C57BL6/J background (n . 10) and were bred in our facility under specific pathogen-free conditions. CD40LTg mice (14) , IL-10-GFP reporter mice (18), JH 2/2 mice (19), and Blimp-1-GFP reporter mice (20) were described before. IFN-a/bR 2/2 mice and programmed cell death protein 1 (PD-1) 2/2 mice were the gifts of D. Moskofidis (Georgia Regents University) and T. Honjo (Kyoto University), respectively. Typical experiments used mice at 6-12 wk of age. For immunization and inflammatory challenge, mice 6-10 wk of age were given an i.p. challenge with 100 ml PBS containing 2 mg alum (Sigma-Aldrich) with or without 200 mg OVA. All studies were reviewed and approved by the institutional animal care and use committee.
Abs and reagents
Abs used in this study were against I-A b (AF6-120.1), CD4 (RM4-5), CD11c (HL3), CD8a (53-6.7), CD90.1 (OX-7), TCRb (H57-597), CD19 (1D3), CD21 (7G6), CD23 (B3B4), CD44 (IM7), CD62L (MEL-14), CD103 (M290), CD122 (TMB1), CD127 (A7R34), IFN-g (XMG1.2), B7H-1 (programmed cell death protein ligand 1 [PD-L1]), B7-DC (PD-L1, programmed cell death protein ligand 2 [PD-L2]), CD80, CXCR5-biotin, CD16/ CD32 (2.4G2), and H-2kd (SF1-1.1) from BD Biosciences. StreptavidineFluor780 and Abs against Foxp3 (FJK-16a), CD8b (H35-17.2), MHC-II (M5/114.15.2), CD4 (GK5.1), and PD-1 (J43) were from eBioscience. Peanut agglutinin FITC was from Vector Laboratories (Southfield, MI). Mouse rIL-2 and rIL-27 were from R&D Systems (Minneapolis, MN).
Flow cytometry and cell sorting
For analysis of DCs, spleens were diced and incubated in RPMI 1640/1% FCS containing 0.5 mg/ml collagenase type IV (Sigma-Aldrich) for 30 min at 37˚C; single-cell suspensions were prepared; and RBCs were depleted with ACK lysing buffer (BioWhittaker). Spleen cells were then washed twice with PBS and filtered through nylon mesh in RPMI 1640/1% FCS. For general analysis, cells were pretreated with anti-CD16/CD32 Ab on ice for 15 min and then incubated at 4˚C for 30 min with specific Abs. For intracellular staining for IFN-g and granzyme B, cells were incubated with anti-CD3 Ab (100 ng/ml) for 3 h in the presence of brefeldin A (eBioscience), followed by fixation/permeabilization and staining with anti-IFN-g (BD Bioscience) and anti-granzyme B Ab (Invitrogen). For IL-10-GFP and granzyme B staining, cells were treated with 0.01% paraformaldehyde/ PBS for 5 min and 0.05% Tween 20/PBS for 5 min, followed by antigranzyme B Ab.
Cells were analyzed on a FACS Canto (BD Biosciences) with FlowJo software (Ashland, OR). Singlet lymphocyte gates were set based on forward scatter and side scatter channels, and autofluorescent cells were gated out using a dump channel. Positive gates were set using fluorescently labeled isotypecontrol nonrelevant Abs, or internal nonrelevant cellular populations. IL-10-GFP + gates were set using non-IL-10-GFP reporter cells as a negative control. B cells were sorted from spleen cells using B cell isolation kit (Miltenyi Biotec) by depletion of CD43 + B cells and non-B cells. CD4 T cells, CD8 T cells, and CD11c DCs were sorted from spleen cells using magnetic beads (Miltenyi Biotec), whereas CD62L low CD8 or CD4 T cells were purified using an Aria cell sorter (BD Biosciences).
Cell culture
For CFSE-dilution assays, sorted CD4 and CD8 T cells were labeled with 5 nM CFSE (Invitrogen) for 10 min at 37˚C, followed by washing with cold PBS. Purified B cells (1 3 10 6 ) and DCs (2 3 10 4 ) were cultured with 10 5 CFSE-labeled OT-I, OT-II cells, and CD8 T cells, or FACS Aria-sorted CD62L low CD8 T cells and CD62L low CD4 T cells in 250 ml RPMI 1640/ 10% FCS containing various concentrations of OVA (Sigma-Aldrich) or 100 ng/ml anti-CD3 Ab for 2-3 d. CFSE dilution was analyzed on a FACS Canto (BD Biosciences) with FlowJo software. IL-10 in the culture supernatant was measured by IL-10 ELISA kit (R&D Systems).
In vivo cytotoxicity
Spleen cells or B cells purified were pulsed with 2 mM OVA 257-264 peptide for 2 h at 37˚C. OVA 257-264 peptide-pulsed cells and control, nonpulsed cells were labeled with 3 and 0.3 mM CFSE, respectively, for 3 min at 37˚C. After washing, these two were mixed 1:1 and injected i.v. (10 7 ) into day 10-14 immunized mice. The ratios of CFSE high versus CFSE low B cells in the host spleen were measured after 18 h.
Quantitative RT-PCR
RNA was prepared using a Qiagen mini kit, according to the manufacturer's protocol. cDNA was prepared using a cDNA synthesis kit from SABioscience (Qiagen). Quantitative RT-PCR analyses were performed in triplicate using primers and SYBR Green master mix from SABioscience with an iQ5 cycler (Bio-Rad). Gene expression levels in each sample were normalized against b-actin expression and statistically analyzed with software from SABioscience.
Adoptive transfer
Six-week-old sex-matched RAG-1 2/2 recipient mice received an i.v. injection in 100 ml PBS of either wild-type or CD40LTg B cells (5 3 10 6 ), plus one or other combination of IL-10-deficient or sufficient (IL-10-GFP reporter) CD4 T cells (10 6 ) and CD8 T cells (10 6 ). Likewise, RAG-1 2/2 recipient mice received CD40LTg B cells with IL-10-GFP reporter CD4 T cells (10 6 ) and CD8 T cells (10 6 ) from either PD-1 2/2 or IFN-a/bR 2/2 mice. Two to three weeks after transfer, spleen cells were analyzed by FACS.
Colitis model
Purified naive CD62L + CD44 2 CD8 T cells (10 6 ) by Aria sort from IL-10-GFP wild-type or IL-10 2/2 mice were i.v. transferred into RAG-1 2/2 mice (6-wk-old male) with or without B cells (5 3 10 6 ) from wild-type or CD40LTg mice. The recipients were weighed weekly for clinical signs of disease. After 5 wk of transfer, mice were sacrificed for tissue harvest. Each colon was graded by an experienced pathologist blinded to the treatment group using a 0-3 scoring system to evaluate acute and chronic inflammation, crypt damage, and regeneration. The highest injury score could be as high as 12, and the lowest without injury 1 (physiological inflammation).
Statistics
The p values were determined by applying the two-tailed, two-sample equal variance Student t test or Mann-Whitney U test.
Results

CD40LTg B cells activate CD8 T cells and induce augmented Ag-specific cytotoxic response
Previous studies have shown that in vitro CD40-activated B cells become potent APCs for CD8 T cells and generate augmented Agspecific cytotoxic response (4, 21, 22) . To test whether CD40LTg B cells can activate T cells, CD40LTg and wild-type B cells were cultured with CFSE-labeled OVA-specific CD8 (OT-I), or CD4 (OT-II), TCR Tg T cells in the presence of various amounts of soluble OVA. We found that CD40LTg, but not wild-type, B cells induced proliferation of OT-I, but not OT-II, cells, as evidenced by significantly higher percentage of CFSE low population in the OT-I cell culture, in a manner dependent on the amounts of OVA (Fig. 1A) . Also, at 2 wk after immunization with OVA plus alum, CD40LTg mice generated significantly greater numbers of OVAspecific tetramer-binding CD8 T cells (Fig. 1B) with augmented OVA-specific in vivo cytotoxicity compared with wild-type control mice (Fig. 1C) . It should be noted that DCs in Tg mice were not functionally activated (16) 
Adjuvant induces activation of natural memory-like CD8 T cells in CD40LBTg mice
During the immunization experiment described above, we found that, unlike wild-type control mice, CD40LTg mice exhibited spontaneous global activation of CD8 T cells in their spleen with accumulation of CD62L low CD44 high/int CD8 T cells. This was substantially augmented after i.p. alum (2 mg) injection even without Ag ( Fig. 2A) , although the accumulation of CD62L low CD44
high/int CD4 T cells was not so obvious (data not shown). At 2 wk after alum injection, significantly higher levels of CD4 and CD8 T cells in CD40LTg mice were still in cell cycle, as judged by 24-h BrdU labeling compared with those in wild-type mice (Fig. 2B) . The proliferating BrdU + CD8 T cells were CXCR5 + CD62L low CD44 high/int with effector memory T (T EM ) phenotype (Fig. 2B) , which are similar to those found in the B cell mantle zone of human tonsils (23 + CD4 T cells from CD40LTg mice had a more activated phenotype with downregulated CD62L expression compared with those from wild-type mice (data not shown).
Activated natural effector memory CD8 T cells express IL-10
The CD62L low CD44
high/int CD8 T cells in CD40LTg did not express IFN-g by intracellular staining. By gene expression analysis, we found that CD8 T cells in CD40LTg mice expressed significantly higher levels (67.4-fold) of IL-10 compared with those in wild-type mice. To better track IL-10 differentiation in CD8 T cells, IL-10-GFP reporter mice (18) and Blimp-1-GFP reporter mice (20, 24) were crossed onto a CD40LTg background. As shown in Fig. 2C , the CD62L low CD44 int/low population has a phenotype consistent with effector/effector memory CD8 T cells defined by Blimp-1-GFP reporter expression (20, 24) . This population in CD40LTg/IL-10-GFP mice also expressed elevated PD-1 and IL-10-GFP reporter expression. This population barely contained Foxp3-GFP + cells (data not shown). In IL-10-GFP reporter mice, the level of GFP expression correlates with the amount of IL-10 mRNA (18) . Because the mean fluorescent intensity of IL-10-GFP reporter expression in GFP + CD8 T cells was consistently lower than that in GFP + CD4 T cells (data not shown), we tested whether IL-10-GFP + CD8 T cells in 
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CD40LTg mice produce IL-10. Thus, CD62L low CD8 and CD4 T cells enriched with IL-10-GFP + cells were purified from CD40LTg and restimulated with anti-CD3 Ab in the presence of wild-type or CD40LTg B cells. As expected and shown in Fig. 2D , the amount of IL-10 produced by CD62L low CD8 T cells was significantly lower than that produced by CD4 T cells from these mice. 3A). In addition, their CD4 and CD8 T cells had significantly higher frequencies of IL-10-GFP expression compared with those in the recipients of wild-type B cells (Fig. 3B) CD8 T cells significantly increased when CD8 T cells lacked IL-10, and this was not further increased when CD4 T cells were also IL-10 deficient (Fig. 3C) . These results indicate that autonomous IL-10 expression in CD8 T cells is critical to counterregulate their overactivation and granzyme B expression when CD40LTg B cells stimulate CD8 T cells.
CD40LTg B cells induce IL-10-GFP expression in T cells
during lymphopenic proliferation Based on the CD8 T cell IL-10 expression in CD40LTg mice during alum-induced inflammatory response, we hypothesized that CD40LTg B cells stimulate memory-like CD8 T cells to express IL-10. To test the hypothesis, we performed adoptive transfer experiments
IFN-a/bR and PD-1 signaling is essential for effector memory CD8 T cells to express IL-10
Type I IFN signaling is critical for CD8 downregulation (26) and PD-1 up-regulation on CD8 T cells (27) upon TCR engagement. PD-1 engagement has been shown to induce IL-10 expression in T cells (28) . As shown in (29) . Using this model, we tested whether cotransfer of CD40LTg B cells could suppress this CD8 T cell-mediated inflammatory response with induction of IL-10. As previously reported, RAG-1 2/2 recipients of naive CD8 T cells significantly lost body weight (Fig. 4A) in association with the differentiation of IL-17 + and IFN-g + effector CD8 T cells in their mesenteric lymph nodes (MLNs) and spleen (Fig. 4B) . As shown in Fig. 4A , cotransfer of CD40LTg, but not wild-type, B cells could suppress inflammation and maintained the body weight of recipient RAG-1 2/2 mice during the period studied. Also, the frequency of IL-17 + , but not IFN-g + , CD8 T cells was significantly reduced in the spleen (data not shown) and MLNs (Fig. 4B) of the recipients of CD40LTg B cells compared with recipients of wild-type B cells or without B cell transfer. As expected, CD8 T cells of the recipients of CD40LTg B cells had a significantly higher frequency of IL-10-GFP expression compared with those in the recipients of wild-type B cells (Fig.  4C) . By histology, colon pathology was significantly improved in the recipients of CD8 T cells with B cell transfer compared with the recipients of CD8 T cells alone, and this was even more significant in the recipients with CD40LTg B cell cotransfer, compared with wild-type B cell cotransfer, in association with reduced lymphocyte infiltration in the colon (Fig. 4D) .
To test whether CD8 T cell IL-10 expression is essential for the regulation of inflammatory response by CD40LTg B cells, IL-10 CD8 T cells also exhibited enhanced lymphocyte infiltration into the colon tissues, although the clinical scoring of this effect was not statistically significant (Fig. 4G ). These results demonstrate that CD40LTg B cells are capable of suppressing systemic as well as intestinal inflammation in spontaneously proliferating CD8 T cells under lymphopenic conditions by inducing IL-10 expression.
Discussion
Using CD40LTg B cells as a model for B cells in human inflammatory diseases that abnormally express CD40L or constitutively receive CD40L, this study presents the possibility that such B cells induce suppressive mechanisms in memory-like T cells with IL-10 expression. Furthermore, this study demonstrates in a mouse model that adoptive transfer of CD40LTg B cells can regulate inflammatory CD8 T cell response under lymphopenia, indicating a potential therapeutic use of CD40L-expressing B cells in CD8 T cell-mediated inflammatory diseases.
Lymphopenia, a condition characterized by reduced numbers of lymphocytes, is a critical cofactor of autoimmunity (30) (31) (32) . Under lymphopenic conditions, residual low numbers of CD8 T cells proliferate in response to cytokines and self-and commensal bacterial Ags presented by DCs (25, 29) , and quickly form memory-like cells. Such memory-like cells are functionally indistinguishable from adaptive memory T cells to provide immediate protection (33) , but may cause tissue damage. In the absence or failure of regulatory mechanisms, self-and microbial reactive T cells are abnormally activated and differentiated into inflammatory IL-17 and IFN-g effector cells to cause autoimmune diseases (31, 32) . Lymphopenia-induced proliferation of autoreactive CD8 T cells closely correlates with the onset of diabetes in NOD mice (34) . Furthermore, memory-like CD8 and CD4 T cells cooperate to break peripheral tolerance under lymphopenic conditions in an autoimmune diabetes model (35) . These studies collectively support the notion that regulating effector differentiation of CD8 T cells during lymphopenic proliferation is a critical therapeutic target for autoimmune diseases.
In the autoimmune NOD mouse diabetes model, a nanoparticle vaccine coated with peptide-MHC complex could prevent and cure diabetes by selective expansion of low-affinity memory-like autoregulatory CD8 T cells, in an epitope-specific manner, to blunt the activation and recruitment of CD8 T cells with other specificities to the islets (36) . In this context, CD40LTg B cells induced the expansion of effector memory-like CD8 T cells under lymphopenia (Fig. 3A) and substantially reduced recruitment of CD8 T cells to the colon compared with wild-type B cells (Fig.  4D) . It is interesting to speculate that CD40L-expressing B cells have a capacity similar to the nanoparticle vaccine and may be used for an adoptive cell transfer therapy to treat CD8 T cellmediated inflammatory autoimmune diseases.
The current study identified CD40LTg B cells to be potent APCs for CD8 T cells, which can be used for a therapeutic target. In fact, accumulating evidence indicates a potential physical interaction between memory-like CD8 T cells and B cells under physiological settings. In a human/SCID rheumatoid arthritis model, IFN-g + CD40L + CD8 T cells in the mantle zone were required for the maintenance of ectopic germinal centers (37) . In tonsils, CXCR5 + CD44 high memory-like CD8 T cells found in the mantle zone supported B cell Ab production (23) . In a viral infection model, long-lived memory CD8 T cells were mainly found in B cell follicles (38) . More recently, it was shown that MZ B cell numbers are determined by perforin-mediated CD8 T cell cytotoxicity (39) . Further studies are needed to examine the role and significance of interactions between CD40-activated B cells and memory-like CD8 T cells in immune response.
In line with the mechanisms of CD8 T cell activation by B cells, previous studies showed that anti-CD40-activated B cells modulated T cell response via overproduction of the cytokines IL-6, IL-10, and IL-15 (4, 40, 41) . Also, injection of agonistic anti-CD40 Abs into mice induced bystander proliferation of memory-like CD8 T cells in a manner dependent on CD40 expression on APCs (i.e., B cells and DCs) and IL-15 (42) . In our model, naive CD40LTg B cells expressed relatively higher levels of IL-6, IL-10, and IL-15 mRNAs (2.5-, 2.0-, and 2.0-fold, respectively) compared with wild-type B cells. Also, CD21 high CD23
low MZ B cells from CD40LTg mice produced greater amounts of IL-6 and IL-10 in response to various stimuli compared with those from control mice (P.A. Koni, A. Bolduc, M. Takezaki, Y. Ametani, Kamanaka, R.A. Flavell, A.L. Mellor, T. Tsubata, and M. Shimoda, manuscript in preparation). Thus, overproduction of certain cytokines could also be a mechanism of augmented CD8 T cell response in CD40LTg mice. Another potential mechanism for memory CD8 T cell activation by CD40LTg B cells could be through CD40 expressed on memory CD8 T cells (43) , although this was not the case in bystander proliferation of memory-like CD8 T cells induced by agonistic anti-CD40 Abs (42) . Further studies are needed to understand the molecular mechanisms of CD8 T cell activation by CD40L-expressing B cells for therapeutic use.
IL-10 expression has been found in virus-specific exhausted CD8 T cells (44, 45) under chronic infection and was implicated as a regulatory mechanism to prevent overactivation. In this context, the current study demonstrates that the absence of IL-10 expression in CD8 T cells increased granzyme B expression (Fig. 3C) , inflammatory cytokine production (Fig. 4E) , and lymphocyte infiltration in the colon (Fig. 4F) . Thus, autonomous IL-10 expression is a critical safeguard mechanism in activated memory CD8 T cells to counterregulate overactivation and block inflammatory response. In a viral infection model, IL-10 production by cytotoxic T cells was amplified by IL-2 derived from CD4 + Th cells with innate-derived IL-27 through a Blimp-1-dependent mechanism (46) . Like in this chronic viral infection model, Blimp-1 and PD-1 expression coincided with IL-10 reporter expression in CD8 T EM cells in our model (Fig. 2C) . Furthermore, based on the data presented in Fig. 3D , we propose IL-10 expression in CD8 T cells to proceed at least in two steps. First, the IL-10 expression is induced under IFN-I signaling as a part of IFN-I-mediated regulatory mechanisms such as downregulation of CD8a to desensitize TCR signaling (26) . Next, the IL-10 expression is dramatically upregulated through PD-1 engagement. In CD8 T cells, IFN-I induces IFN regulatory factor 9 that directly enhances PD-1 expression at the transcriptional level (27) . PD-1 and the PD-L1/PD-L2 interaction critically regulates self-reactive CD8 T cell activation in various autoimmune disease models (47) via induction of CD8 T cell anergy (unresponsive) by limiting their autonomous IL-2 production (48) as well as by causing exhaustion in fully differentiated effector CD8 T cells to block cytotoxicity in association with upregulation of various negative regulators (49, 50) . In this context, we show that IL-10 expression also is one of the critical regulatory mechanisms mediated by PD-1 engagement.
Finally, our finding may be related to regulatory B cell functions, which are induced by anti-CD40 activation (51) (52) (53) . Regulatory functions of B cells have been mainly associated with their own overproduction of IL-10 (41, 52, 54, 55) . In addition, the current study suggests that the regulatory action of anti-CD40-activated B cells may, in fact, involve induction of IL-10 in the memory-like CD4 and CD8 T cell compartment. Whereas such a mechanism is certainly important to prevent excessive tissue damage in infections (45) , colitis, and other autoimmune diseases, it might also play an adverse role in chronic infections and malignancies by creating an immune-suppressive environment that impairs overall T cell function. Thus, our findings may be helpful to treat patients with chronic inflammatory diseases.
